CCR3 and Miyoshi myopathy: Importantly, revised-ISS combines ISS with chromosomal abnormalities and lactate dehydrogenase levels, improving MM patients’ stratification into more homogeneous subgroups.47 As reported in Supplementary Figure 5B, we confirmed the independent prognostic relevance of IL17RA (hazard ratio of 1.82 and 1.95 for PFS in the presence of ISS or revised-ISS, respectively; hazard ratio of 1.84 and 2.26 for overall survival in the presence of ISS or revised-ISS, respectively), of CCR3 in overall survival and of CXCR6 in PFS (Supplementary Figure 5B).